By enhancing PARP1 activity [93], increasing the BER capacity in cells [105] and stabilizing stalled replication forks [101], HMGA2 limits the efficacy of 5-FU and Capecitabine in CRC patients with HMGA2-expressing tumors. This evidence concerns the gene PARP1 and colorectal carcinoma.